ProcuraAxisBeta
Sign inCreate Free Account
Home / Opportunities / Opportunity
PROCUREMENT OPPORTUNITY

Tumour Infiltrating Lymphocyte (TIL) Therapy hubs for Melanoma (Adults)

NHS England · compiled

Tender information last checkedLast checked 30 Sept 2026, 01:51.

Opportunity overview

NHS Arden and Greater East Midlands Commissioning Support Unit (AGCSU), on behalf of NHS England -Specialised Commissioning (referred to as the Authority), is inviting suitably qualified and experienced providers to respond to this Competitive Process for the provision of Tumour Infiltrating Lymphocyte (TIL) Therapy hubs for Melanoma (Adults).<br/><br/>As a result of this procurement exercise an agreement will be established with the successful bidder(s) for a period of three (3) years with the Commissioners having the option to extend for up to an additional two (2) year(s) (maximum contract duration 5 years).<br/><br/>The deadline for submissions is 12.00pm (noon) on Tuesday 24th June 2025.

Classification

  • CPV85100000 — Health services

Lots

  • Lot 1 - London (2 Sites)£17.5m
  • Lot 2 - East of England (1 Site)£8.7m
  • Lot 3 - South East (1 Site)£8.7m
  • Lot 4 - South West (1 Site)£8.7m
  • Lot 5 - Midlands (1 Site)£8.7m
  • Lot 6 - North East and Yorkshire (1 Site)£8.7m
  • Lot 7 - North West (1 Site)£8.7m

Published notice details

Additional information from the published procurement release. Fields appear only when supplied by the source; check the original notice and tender documents before acting.

Scope, procedure and submissions

Id
ocds-h6vhtk-0515a8
Status
active
Has Recurrence
Yes
Procurement Method
open
Main Procurement Category
services
Procurement Method Details
Open procedure

Covered By

GPA

Amendments

Entry 1
Id
1

Unstructured Changes

Entry 1

Where

Section
VI.3.0.1

New Value

Text
The key objectives of the Procurement are to commission eight (8) Tumour Infiltrating Lymphocyte (TIL) Therapy Hubs for adult patients, for the provision of Lifileucel for previously treated unresectable or metastatic melanoma, across seven (7) geographical lots as outlined below, to serve the population of England.Lot 1: London (2 sites)Lot 2: East of England (1 site)Lot 3: South East (1 site)Lot 4: South West (1 site)Lot 5: Midlands (1 site)Lot 6: North East and Yorkshire (1 site)Lot 7: North West (1 site)Bidders are to note that Providers must be located in and deliver services from the defined geographical area(s) that they are interested in providing services to.Link to NHS England Regions:NHS England » Regional teams (https://www.england.nhs.uk/about/regional-area-teams/).Lifileucel is a first in class autologous tumour infiltrating lymphocyte (TIL) cell therapy. This infusion is followed by a short course of interleukin-2 (IL-2). IL-2 is a potent drug and has the potential to cause significant side effects. As such, it is recommended that patients receive treatment at a Trust with immediate access to Intensive Therapy Unit (ITU).Lifileucel is being assessed via NICE’s technology appraisal programme for previously treated unresectable or metastatic melanoma in adults, with an expected final guidance publication date of 10th December 2025.Link for the current NICE paperwork:https://www.nice.org.uk/guidance/indevelopment/gid-ta10752Providers are required to be an established site for the delivery of specialist skin cancer care that complies with the requirements as set out in the following specification: https://www.england.nhs.uk/wp-content/uploads/2018/08/Cancer-skin-adult.pdfProviders must also;• Have access to surgical expertise which enables them to perform tumour resections to obtain enough sample tissue for final product to be made.• hold the appropriate Human Tissue Authority licences, which includes having the licence to cover the procurement, donor testing and exporting of the resected tissue.• Have expertise in delivering and managing cellular therapies• Have experience of managing the adverse effects of interleukin 2 inhibitors. Examples of these adverse events would be those similar to cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome.• Hold a Joint Accreditation Committee of ISCT and EBMT of the European Society for Blood and Marrow Transplantation (JACIE) Immune Effector Cells (IEC) accreditation or be working towards such accreditation.• Be a Heamotopoietic Stem Cell Transplantation centreProviders must be able to meet the requirements set out in this Competitive Process and deliver the contract in accordance with its terms.To express interest and participate in the Competitive Process, please register and apply via Atamis esourcing portal https://health-family.force.com/s/WelcomeShould Tenderers have any queries, or problems using the portal, they should contact the Helpdesk at:Phone: 0800 9956035E-mail: support-health@atamis.co.ukThe closing date for completed Competitive Process responses is 12:00pm (noon), on Tuesday 24th June 2025.Atamis Project reference C341701The contract duration is for three (3) years with the Commissioners having the option to extend for up to an additional two (2) year(s) (maximum contract duration five (5) years).This is a Provider Selection Regime (PSR) Contract Notice. The awarding of this contract is subject to the Health Care Services (Provider Selection Regime) Regulations 2023. For the avoidance of doubt, the provisions of the Public Contracts Regulations 2015 do not apply to this award.The decision maker of the award will be: NHS England

Old Value

Text
The key objectives of the Procurement are to commission eight (8) Tumour Infiltrating Lymphocyte (TIL) Therapy Hubs for adult patients, for the provision of Lifileucel for previously treated unresectable or metastatic melanoma, across seven (7) geographical lots as outlined below, to serve the population of England. Lot 1: London (2 sites)Lot 2: East of England (1 site)Lot 3: South East (1 site)Lot 4: South West (1 site)Lot 5: Midlands (1 site)Lot 6: North East and Yorkshire (1 site)Lot 7: North West (1 site)Bidders are to note that Providers must be located in and deliver services from the defined geographical area(s) that they are interested in providing services to. Link to NHS England Regions:NHS England » Regional teams (https://www.england.nhs.uk/about/regional-area-teams/). Lifileucel is a first in class autologous tumour infiltrating lymphocyte (TIL) cell therapy. This infusion is followed by a short course of interleukin-2 (IL-2). IL-2 is a potent drug and has the potential to cause significant side effects. As such, it is recommended that patients receive treatment at a Trust with immediate access to Intensive Therapy Unit (ITU). Lifileucel is being assessed via NICE’s technology appraisal programme for previously treated unresectable or metastatic melanoma in adults, with an expected final guidance publication date of 10th December 2025. Link for the current NICE paperwork:https://www.nice.org.uk/guidance/indevelopment/gid-ta10752Providers are required to be an established site for the delivery of specialist skin cancer care that complies with the requirements as set out in the following specification: https://www.england.nhs.uk/wp-content/uploads/2018/08/Cancer-skin-adult.pdfProviders must also;• Have access to surgical expertise which enables them to perform tumour resections to obtain enough sample tissue for final product to be made. • hold the appropriate Human Tissue Authority licences, which includes having the licence to cover the procurement, donor testing and exporting of the resected tissue.• Have expertise in delivering and managing cellular therapies • Have experience of managing the adverse effects of interleukin 2 inhibitors. Examples of these adverse events would be those similar to cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome.• Hold a Joint Accreditation Committee of ISCT and EBMT of the European Society for Blood and Marrow Transplantation (JACIE) Immune Effector Cells (IEC) accreditation or be working towards such accreditation. • Be a Heamotopoietic Stem Cell Transplantation centre Providers must be able to meet the requirements set out in this Competitive Process and deliver the contract in accordance with its terms.To express interest and participate in the Competitive Process, please register and apply via Atamis esourcing portal https://health-family.force.com/s/WelcomeShould Tenderers have any queries, or problems using the portal, they should contact the Helpdesk at: Phone: 0800 9956035E-mail: support-health@atamis.co.ukThe closing date for completed Competitive Process responses is 12:00pm (noon), on Tuesday 24th June 2025.Atamis Project reference C41701The contract duration is for three (3) years with the Commissioners having the option to extend for up to an additional two (2) year(s) (maximum contract duration five (5) years).This is a Provider Selection Regime (PSR) Contract Notice. The awarding of this contract is subject to the Health Care Services (Provider Selection Regime) Regulations 2023. For the avoidance of doubt, the provisions of the Public Contracts Regulations 2015 do not apply to this award.The decision maker of the award will be: NHS England
Entry 2
Id
2

Unstructured Changes

Entry 1

Where

Section
IV.2.2.1

New Value

Date
1 Jul 2025, 12:00

Old Value

Date
24 Jun 2025, 12:00
Entry 2

Where

Section
IV.2.7.1

New Value

Date
1 Jul 2025, 12:00

Old Value

Date
24 Jun 2025, 12:00
Entry 3

Where

Section
II.1.4.1

New Value

Text
NHS Arden and Greater East Midlands Commissioning Support Unit (AGCSU), on behalf of NHS England -Specialised Commissioning (referred to as the Authority), is inviting suitably qualified and experienced providers to respond to this Competitive Process for the provision of Tumour Infiltrating Lymphocyte (TIL) Therapy hubs for Melanoma (Adults).As a result of this procurement exercise an agreement will be established with the successful bidder(s) for a period of three (3) years with the Commissioners having the option to extend for up to an additional two (2) year(s) (maximum contract duration 5 years).The deadline for submissions is 12.00pm (noon) on Tuesday 1st July 2025.

Old Value

Text
NHS Arden and Greater East Midlands Commissioning Support Unit (AGCSU), on behalf of NHS England -Specialised Commissioning (referred to as the Authority), is inviting suitably qualified and experienced providers to respond to this Competitive Process for the provision of Tumour Infiltrating Lymphocyte (TIL) Therapy hubs for Melanoma (Adults).As a result of this procurement exercise an agreement will be established with the successful bidder(s) for a period of three (3) years with the Commissioners having the option to extend for up to an additional two (2) year(s) (maximum contract duration 5 years).The deadline for submissions is 12.00pm (noon) on Tuesday 24th June 2025.
Entry 4

Where

Section
VI.3.0.1

New Value

Text
The key objectives of the Procurement are to commission eight (8) Tumour Infiltrating Lymphocyte (TIL) Therapy Hubs for adult patients, for the provision of Lifileucel for previously treated unresectable or metastatic melanoma, across seven (7) geographical lots as outlined below, to serve the population of England. Lot 1: London (2 sites)Lot 2: East of England (1 site)Lot 3: South East (1 site)Lot 4: South West (1 site)Lot 5: Midlands (1 site)Lot 6: North East and Yorkshire (1 site)Lot 7: North West (1 site)Bidders are to note that Providers must be located in and deliver services from the defined geographical area(s) that they are interested in providing services to. Link to NHS England Regions:NHS England » Regional teams (https://www.england.nhs.uk/about/regional-area-teams/). Lifileucel is a first in class autologous tumour infiltrating lymphocyte (TIL) cell therapy. This infusion is followed by a short course of interleukin-2 (IL-2). IL-2 is a potent drug and has the potential to cause significant side effects. As such, it is recommended that patients receive treatment at a Trust with immediate access to Intensive Therapy Unit (ITU). Lifileucel is being assessed via NICE’s technology appraisal programme for previously treated unresectable or metastatic melanoma in adults, with an expected final guidance publication date of 10th December 2025. Link for the current NICE paperwork:https://www.nice.org.uk/guidance/indevelopment/gid-ta10752Providers are required to be an established site for the delivery of specialist skin cancer care that complies with the requirements as set out in the following specification: https://www.england.nhs.uk/wp-content/uploads/2018/08/Cancer-skin-adult.pdfProviders must also;• Have access to surgical expertise which enables them to perform tumour resections to obtain enough sample tissue for final product to be made. • hold the appropriate Human Tissue Authority licences, which includes having the licence to cover the procurement, donor testing and exporting of the resected tissue.• Have expertise in delivering and managing cellular therapies • Have experience of managing the adverse effects of interleukin 2 inhibitors. Examples of these adverse events would be those similar to cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome.• Hold a Joint Accreditation Committee of ISCT and EBMT of the European Society for Blood and Marrow Transplantation (JACIE) Immune Effector Cells (IEC) accreditation or be working towards such accreditation. • Be a Heamotopoietic Stem Cell Transplantation centre Providers must be able to meet the requirements set out in this Competitive Process and deliver the contract in accordance with its terms.To express interest and participate in the Competitive Process, please register and apply via Atamis esourcing portal https://health-family.force.com/s/WelcomeShould Tenderers have any queries, or problems using the portal, they should contact the Helpdesk at: Phone: 0800 9956035E-mail: support-health@atamis.co.ukThe closing date for completed Competitive Process responses is 12.00pm (noon) on Tuesday 1st July 2025.Atamis Project reference C341701The contract duration is for three (3) years with the Commissioners having the option to extend for up to an additional two (2) year(s) (maximum contract duration five (5) years).This is a Provider Selection Regime (PSR) Contract Notice. The awarding of this contract is subject to the Health Care Services (Provider Selection Regime) Regulations 2023. For the avoidance of doubt, the provisions of the Public Contracts Regulations 2015 do not apply to this award.The decision maker of the award will be: NHS England

Old Value

Text
The key objectives of the Procurement are to commission eight (8) Tumour Infiltrating Lymphocyte (TIL) Therapy Hubs for adult patients, for the provision of Lifileucel for previously treated unresectable or metastatic melanoma, across seven (7) geographical lots as outlined below, to serve the population of England. Lot 1: London (2 sites)Lot 2: East of England (1 site)Lot 3: South East (1 site)Lot 4: South West (1 site)Lot 5: Midlands (1 site)Lot 6: North East and Yorkshire (1 site)Lot 7: North West (1 site)Bidders are to note that Providers must be located in and deliver services from the defined geographical area(s) that they are interested in providing services to. Link to NHS England Regions:NHS England » Regional teams (https://www.england.nhs.uk/about/regional-area-teams/). Lifileucel is a first in class autologous tumour infiltrating lymphocyte (TIL) cell therapy. This infusion is followed by a short course of interleukin-2 (IL-2). IL-2 is a potent drug and has the potential to cause significant side effects. As such, it is recommended that patients receive treatment at a Trust with immediate access to Intensive Therapy Unit (ITU). Lifileucel is being assessed via NICE’s technology appraisal programme for previously treated unresectable or metastatic melanoma in adults, with an expected final guidance publication date of 10th December 2025. Link for the current NICE paperwork:https://www.nice.org.uk/guidance/indevelopment/gid-ta10752Providers are required to be an established site for the delivery of specialist skin cancer care that complies with the requirements as set out in the following specification: https://www.england.nhs.uk/wp-content/uploads/2018/08/Cancer-skin-adult.pdfProviders must also;• Have access to surgical expertise which enables them to perform tumour resections to obtain enough sample tissue for final product to be made. • hold the appropriate Human Tissue Authority licences, which includes having the licence to cover the procurement, donor testing and exporting of the resected tissue.• Have expertise in delivering and managing cellular therapies • Have experience of managing the adverse effects of interleukin 2 inhibitors. Examples of these adverse events would be those similar to cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome.• Hold a Joint Accreditation Committee of ISCT and EBMT of the European Society for Blood and Marrow Transplantation (JACIE) Immune Effector Cells (IEC) accreditation or be working towards such accreditation. • Be a Heamotopoietic Stem Cell Transplantation centre Providers must be able to meet the requirements set out in this Competitive Process and deliver the contract in accordance with its terms.To express interest and participate in the Competitive Process, please register and apply via Atamis esourcing portal https://health-family.force.com/s/WelcomeShould Tenderers have any queries, or problems using the portal, they should contact the Helpdesk at: Phone: 0800 9956035E-mail: support-health@atamis.co.ukThe closing date for completed Competitive Process responses is 12:00pm (noon), on Tuesday 24th June 2025.Atamis Project reference C41701The contract duration is for three (3) years with the Commissioners having the option to extend for up to an additional two (2) year(s) (maximum contract duration five (5) years).This is a Provider Selection Regime (PSR) Contract Notice. The awarding of this contract is subject to the Health Care Services (Provider Selection Regime) Regulations 2023. For the avoidance of doubt, the provisions of the Public Contracts Regulations 2015 do not apply to this award.The decision maker of the award will be: NHS England
Entry 3
Id
3

Unstructured Changes

Entry 1

Where

Section
II.1.4.1

New Value

Text
NHS England has taken the decision to abandon this competitive provider selection process (effective from 30th June 2025) for lifileucel, a cellular therapy for previously treated unresectable or metastatic melanoma (NICE ID 3863). NHS England remains committed to commissioning this service, as this tumour infiltrating lymphocyte cell therapy progresses through the NICE TA process, in line with the relevant procurement regulations and intends to progress this at the earliest suitable opportunity. Any future opportunities will be advertised in line with these the relevant procurement regulations, for example via the Find a Tender Service, and we will also notify all providers registered against the current process.This is a Provider Selection Regime (PSR) notice that this provider selection process has been abandoned and a contract has not been awarded. This process has been abandoned under the Health Care Services (Provider Selection Regime) Regulations 2023. For the avoidance of doubt, the provisions of the Public Contracts Regulations 2015 do not apply.

Old Value

Text
NHS Arden and Greater East Midlands Commissioning Support Unit (AGCSU), on behalf of NHS England -Specialised Commissioning (referred to as the Authority), is inviting suitably qualified and experienced providers to respond to this Competitive Process for the provision of Tumour Infiltrating Lymphocyte (TIL) Therapy hubs for Melanoma (Adults).As a result of this procurement exercise an agreement will be established with the successful bidder(s) for a period of three (3) years with the Commissioners having the option to extend for up to an additional two (2) year(s) (maximum contract duration 5 years).The deadline for submissions is 12.00pm (noon) on Tuesday 24th June 2025.

Bid Opening

Date
24 Jun 2025, 12:00

Legal basis

Id
32014L0024
Scheme
CELEX

Lot Details

Maximum Lots Bid Per Supplier
1
Maximum Lots Awarded Per Supplier
1

Expected award period

Starts
24 Jun 2025, 12:00

Tender Period

Ends
24 Jun 2025, 12:00

Communication

Classification

Id
85100000
Scheme
CPV
Description
Health services

Submission terms

Languages

en

Bid Validity Period

Ends
21 Dec 2025, 23:59

Submission Method

electronicSubmission
written

Lots and requirements

Entry 1
Id
1
Title
Lot 1 - London (2 Sites)
Status
active
Has Options
Yes
Has Renewal
No
Description
The key objectives of the Procurement are to commission eight (8) Tumour Infiltrating Lymphocyte (TIL) Therapy Hubs for adult patients, for the provision of Lifileucel for previously treated unresectable or metastatic melanoma, with two (2) sites in London. <br/><br/>Providers may only bid for one Lot. Bids submitted for multiple lots will not be considered. <br/><br/>Bidders are to note that Providers must be located in and deliver services from the defined geographical area(s) that they are interested in providing services to. <br/><br/>Link to NHS England Regions:<br/>NHS England » Regional teams (https://www.england.nhs.uk/about/regional-area-teams/).<br/><br/>As a result of this procurement exercise an agreement will be established with the successful bidder(s) for a period of three (3) years with the Commissioners having the option to extend for up to an additional two (2) year(s) (maximum contract duration 5 years).<br/><br/>The deadline for submissions is 12.00pm (noon) on Tuesday 24th June 2025.

Value

Amount
17,470,000
Currency
GBP

Options

Description
Following the initial 3 year contract period, there is an option to extend for up to an additional 2 year(s)

Contract period

Ends
30 Oct 2030, 23:59
Starts
31 Oct 2025, 00:00

Submission terms

Variant Policy
notAllowed
Entry 2
Id
2
Title
Lot 2 - East of England (1 Site)
Status
active
Has Options
Yes
Has Renewal
No
Description
The key objectives of the Procurement are to commission eight (8) Tumour Infiltrating Lymphocyte (TIL) Therapy Hubs for adult patients, for the provision of Lifileucel for previously treated unresectable or metastatic melanoma, with one (1) site in the East of England. <br/><br/>Providers may only bid for one Lot. Bids submitted for multiple lots will not be considered. <br/><br/>Bidders are to note that Providers must be located in and deliver services from the defined geographical area(s) that they are interested in providing services to. <br/><br/>Link to NHS England Regions:<br/>NHS England » Regional teams (https://www.england.nhs.uk/about/regional-area-teams/).<br/><br/>As a result of this procurement exercise an agreement will be established with the successful bidder(s) for a period of three (3) years with the Commissioners having the option to extend for up to an additional two (2) year(s) (maximum contract duration 5 years).<br/><br/>The deadline for submissions is 12.00pm (noon) on Tuesday 24th June 2025.

Value

Amount
8,740,000
Currency
GBP

Options

Description
Following the initial 3 year contract period, there is an option to extend for up to an additional 2 year(s)

Contract period

Ends
30 Oct 2030, 23:59
Starts
31 Oct 2025, 00:00

Submission terms

Variant Policy
notAllowed
Entry 3
Id
3
Title
Lot 3 - South East (1 Site)
Status
active
Has Options
Yes
Has Renewal
No
Description
The key objectives of the Procurement are to commission eight (8) Tumour Infiltrating Lymphocyte (TIL) Therapy Hubs for adult patients, for the provision of Lifileucel for previously treated unresectable or metastatic melanoma, with one (1) site in the South East. <br/><br/>Providers may only bid for one Lot. Bids submitted for multiple lots will not be considered. <br/><br/>Bidders are to note that Providers must be located in and deliver services from the defined geographical area(s) that they are interested in providing services to. <br/><br/>Link to NHS England Regions:<br/>NHS England » Regional teams (https://www.england.nhs.uk/about/regional-area-teams/).<br/><br/>As a result of this procurement exercise an agreement will be established with the successful bidder(s) for a period of three (3) years with the Commissioners having the option to extend for up to an additional two (2) year(s) (maximum contract duration 5 years).<br/><br/>The deadline for submissions is 12.00pm (noon) on Tuesday 24th June 2025.

Value

Amount
8,740,000
Currency
GBP

Options

Description
Following the initial 3 year contract period, there is an option to extend for up to an additional 2 year(s)

Contract period

Ends
30 Oct 2030, 23:59
Starts
31 Oct 2025, 00:00

Submission terms

Variant Policy
notAllowed
Entry 4
Id
4
Title
Lot 4 - South West (1 Site)
Status
active
Has Options
Yes
Has Renewal
No
Description
The key objectives of the Procurement are to commission eight (8) Tumour Infiltrating Lymphocyte (TIL) Therapy Hubs for adult patients, for the provision of Lifileucel for previously treated unresectable or metastatic melanoma, with one (1) site in the South West. <br/><br/>Providers may only bid for one Lot. Bids submitted for multiple lots will not be considered. <br/><br/>Bidders are to note that Providers must be located in and deliver services from the defined geographical area(s) that they are interested in providing services to. <br/><br/>Link to NHS England Regions:<br/>NHS England » Regional teams (https://www.england.nhs.uk/about/regional-area-teams/).<br/><br/>As a result of this procurement exercise an agreement will be established with the successful bidder(s) for a period of three (3) years with the Commissioners having the option to extend for up to an additional two (2) year(s) (maximum contract duration 5 years).<br/><br/>The deadline for submissions is 12.00pm (noon) on Tuesday 24th June 2025.

Value

Amount
8,740,000
Currency
GBP

Options

Description
Following the initial 3 year contract period, there is an option to extend for up to an additional 2 year(s)

Contract period

Ends
30 Oct 2030, 23:59
Starts
31 Oct 2025, 00:00

Submission terms

Variant Policy
notAllowed
Entry 5
Id
5
Title
Lot 5 - Midlands (1 Site)
Status
active
Has Options
Yes
Has Renewal
No
Description
The key objectives of the Procurement are to commission eight (8) Tumour Infiltrating Lymphocyte (TIL) Therapy Hubs for adult patients, for the provision of Lifileucel for previously treated unresectable or metastatic melanoma, with one (1) site in the Midlands. <br/><br/>Providers may only bid for one Lot. Bids submitted for multiple lots will not be considered. <br/><br/>Bidders are to note that Providers must be located in and deliver services from the defined geographical area(s) that they are interested in providing services to. <br/><br/>Link to NHS England Regions:<br/>NHS England » Regional teams (https://www.england.nhs.uk/about/regional-area-teams/).<br/><br/>As a result of this procurement exercise an agreement will be established with the successful bidder(s) for a period of three (3) years with the Commissioners having the option to extend for up to an additional two (2) year(s) (maximum contract duration 5 years).<br/><br/>The deadline for submissions is 12.00pm (noon) on Tuesday 24th June 2025.

Value

Amount
8,740,000
Currency
GBP

Options

Description
Following the initial 3 year contract period, there is an option to extend for up to an additional 2 year(s)

Contract period

Ends
30 Oct 2030, 23:59
Starts
31 Oct 2025, 00:00

Submission terms

Variant Policy
notAllowed
Entry 6
Id
6
Title
Lot 6 - North East and Yorkshire (1 Site)
Status
active
Has Options
Yes
Has Renewal
No
Description
The key objectives of the Procurement are to commission eight (8) Tumour Infiltrating Lymphocyte (TIL) Therapy Hubs for adult patients, for the provision of Lifileucel for previously treated unresectable or metastatic melanoma, with one (1) site in the North East and Yorkshire.<br/><br/>Providers may only bid for one Lot. Bids submitted for multiple lots will not be considered. <br/><br/>Bidders are to note that Providers must be located in and deliver services from the defined geographical area(s) that they are interested in providing services to. <br/><br/>Link to NHS England Regions:<br/>NHS England » Regional teams (https://www.england.nhs.uk/about/regional-area-teams/).<br/><br/>As a result of this procurement exercise an agreement will be established with the successful bidder(s) for a period of three (3) years with the Commissioners having the option to extend for up to an additional two (2) year(s) (maximum contract duration 5 years).<br/><br/>The deadline for submissions is 12.00pm (noon) on Tuesday 24th June 2025.

Value

Amount
8,740,000
Currency
GBP

Options

Description
Following the initial 3 year contract period, there is an option to extend for up to an additional 2 year(s)

Contract period

Ends
30 Oct 2030, 23:59
Starts
31 Oct 2025, 00:00

Submission terms

Variant Policy
notAllowed
Entry 7
Id
7
Title
Lot 7 - North West (1 Site)
Status
active
Has Options
Yes
Has Renewal
No
Description
The key objectives of the Procurement are to commission eight (8) Tumour Infiltrating Lymphocyte (TIL) Therapy Hubs for adult patients, for the provision of Lifileucel for previously treated unresectable or metastatic melanoma, with one (1) site in the North West. <br/><br/>Providers may only bid for one Lot. Bids submitted for multiple lots will not be considered. <br/><br/>Bidders are to note that Providers must be located in and deliver services from the defined geographical area(s) that they are interested in providing services to. <br/><br/>Link to NHS England Regions:<br/>NHS England » Regional teams (https://www.england.nhs.uk/about/regional-area-teams/).<br/><br/>As a result of this procurement exercise an agreement will be established with the successful bidder(s) for a period of three (3) years with the Commissioners having the option to extend for up to an additional two (2) year(s) (maximum contract duration 5 years).<br/><br/>The deadline for submissions is 12.00pm (noon) on Tuesday 24th June 2025.

Value

Amount
8,740,000
Currency
GBP

Options

Description
Following the initial 3 year contract period, there is an option to extend for up to an additional 2 year(s)

Contract period

Ends
30 Oct 2030, 23:59
Starts
31 Oct 2025, 00:00

Submission terms

Variant Policy
notAllowed

Items and delivery

Item 1
Id
1
Related Lot
1

Delivery locations

Entry 1
Region
UKI

Additional Classifications

Entry 1
Id
85100000
Scheme
CPV
Description
Health services
Item 2
Id
2
Related Lot
2

Delivery locations

Entry 1
Region
UKH

Additional Classifications

Entry 1
Id
85100000
Scheme
CPV
Description
Health services
Item 3
Id
3
Related Lot
3

Delivery locations

Entry 1
Region
UKJ

Additional Classifications

Entry 1
Id
85100000
Scheme
CPV
Description
Health services
Item 4
Id
4
Related Lot
4

Delivery locations

Entry 1
Region
UKK

Additional Classifications

Entry 1
Id
85100000
Scheme
CPV
Description
Health services
Item 5
Id
5
Related Lot
5

Delivery locations

Entry 1
Region
UKF
Entry 2
Region
UKG

Additional Classifications

Entry 1
Id
85100000
Scheme
CPV
Description
Health services
Item 6
Id
6
Related Lot
6

Delivery locations

Entry 1
Region
UKC
Entry 2
Region
UKE

Additional Classifications

Entry 1
Id
85100000
Scheme
CPV
Description
Health services
Item 7
Id
7
Related Lot
7

Delivery locations

Entry 1
Region
UKD

Additional Classifications

Entry 1
Id
85100000
Scheme
CPV
Description
Health services

Buyer, suppliers and contacts

Organisation 1
Id
GB-FTS-130973
Name
NHS England

Roles

buyer

Address

Region
UKJ1
Locality
London
Postal Code
SE1 8UG
Country Name
United Kingdom
Street Address
Wellington House, 133-135 Waterloo Rd

Details

Classifications

Entry 1
Id
BODY_PUBLIC
Scheme
TED_CA_TYPE
Description
Body governed by public law
Entry 2
Id
07
Scheme
COFOG
Description
Health

Identifier

Legal Name
NHS England

Contact

Name
Jessica Gaucher-Thompson
Organisation 2
Id
GB-FTS-141301
Name
NHS Arden and Greater East Midlands Commissioning Support Unit

Roles

reviewBody

Address

Locality
Derby
Postal Code
DE1 3QT
Country Name
United Kingdom
Street Address
Cardinal Square, 10 Nottingham Road

Details

Identifier

Legal Name
NHS Arden and Greater East Midlands Commissioning Support Unit

Recorded locations

  • Buyer location · London · UKJ1 · SE1 8UG · United Kingdom
  • Delivery location · UKC
  • Delivery location · UKD
  • Delivery location · UKE
  • Delivery location · UKF
  • Delivery location · UKG
  • Delivery location · UKH
  • Delivery location · UKI
  • Delivery location · UKJ
  • Delivery location · UKK

Notice and amendment history

1 published notice version reviewed by ProcuraAxis.

1 VERSION
  1. ocds-h6vhtk-0515a8-2025-07-08T13:43:17+01:00compiled ·